Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model

Osteosarcoma is a rare type of bone cancer that affects mostly children and adolescents. First-line chemotherapy for osteosarcoma has not been improved for many decades. Eribulin has been used to treat breast cancer and liposarcoma in the clinic. A patient-derived orthotopic xenograft (PDOX) mouse m...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2021-04, Vol.41 (4), p.1779-1784
Main Authors: Wu, Nathaniel F, Yamamoto, Jun, Aoki, Yusuke, Bouvet, Michael, Hoffman, Robert M
Format: Article
Language:English
Subjects:
Adolescent
Animal models
Animals
Antineoplastic Agents - pharmacology
Biomedical materials
Body size
Body weight
Body weight loss
Bone cancer
Bone Neoplasms - drug therapy
Bone Neoplasms - pathology
Breast cancer
Chemotherapy
Children
Furans - pharmacology
Histology
Humans
Insertion
Ketones - pharmacology
Liposarcoma
Male
Mice
Mice, Nude
Necrosis
Osteosarcoma
Osteosarcoma - drug therapy
Osteosarcoma - pathology
Sarcoma
Tibia
Tibia - drug effects
Tibia - pathology
Tumor Burden - drug effects
Tumors
Weight loss
Xenograft Model Antitumor Assays
Xenografts
Xenotransplantation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma is a rare type of bone cancer that affects mostly children and adolescents. First-line chemotherapy for osteosarcoma has not been improved for many decades. Eribulin has been used to treat breast cancer and liposarcoma in the clinic. A patient-derived orthotopic xenograft (PDOX) mouse model of osteosarcoma was established by tumor insertion within the tibia. This model more closely mimics osteosarcoma in clinical settings and was used to test the efficacy of eribulin. Tibia-insertion osteosarcoma PDOX mouse models were randomized into two groups: a control group (n=4) and an eribulin-treatment group (n=5). Mice were treated for fourteen days, four weeks after initial implantation. Tumor size and body weight were measured, and tumor histology was examined. Significant tumor growth inhibition (p=0.044) was observed in mice treated with eribulin compared to the control group. Histology demonstrated necrosis in the eribulin-treated tumors. There was no body-weight loss in the treated mice. Eribulin may be a clinically-effective, off-label chemotherapy for recalcitrant osteosarcoma that has failed first- and second-line therapy.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14943